Tildrakizumab efficacy and safety are not altered by metabolic syndrome status in patients with psoriasis: Post hoc analysis of 2 phase 3 randomized controlled studies (reSURFACE 1 and reSURFACE 2) - 09/01/20
Doi : 10.1016/j.jaad.2019.09.042
Mark G. Lebwohl, MD a, ⁎ 
, Craig L. Leonardi, MD b, Nehal N. Mehta, MD, MSCE c, Alice B. Gottlieb, MD, PhD d, Alan M. Mendelsohn, MD e, Jeff Parno, MS e, Stephen J. Rozzo, PhD e, Alan Menter, MD f
, Craig L. Leonardi, MD b, Nehal N. Mehta, MD, MSCE c, Alice B. Gottlieb, MD, PhD d, Alan M. Mendelsohn, MD e, Jeff Parno, MS e, Stephen J. Rozzo, PhD e, Alan Menter, MD f a Department of Dermatology, Mount Sinai Hospital, New York, New York
b Central Dermatology and Saint Louis University School of Medicine, St Louis, Missouri
c National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland
d Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, New York
e Sun Pharmaceutical Industries, Inc, Princeton, New Jersey
f Division of Dermatology, Baylor Scott & White, and Texas A&M College of Medicine, Dallas, Texas
∗Reprint requests: Mark G. Lebwohl, MD, Department of Dermatology, Mount Sinai Hospital, 5 E 98th St, NY 10029Department of DermatologyMount Sinai Hospital5 E 98th StNY10029
| Funding sources: Studies were funded by Merck Sharp and Dohme Corp, a subsidiary of Merck & Co, Inc, Kenilworth, New Jersey. These analyses were funded by Sun Pharmaceutical Industries, Inc. |
|
| Conflicts of interest: Dr Lebwohl is an employee of Mount Sinai which which receives research funds from AbbVie, Boehringer Ingelheim, Celgene, Eli Lilly & Co, Incyte, Janssen/Johnson & Johnson, LEO Pharma, MedImmune/AstraZeneca, Novartis, Pfizer, SCIderm, UCB, Valeant, and ViD; receives research funds from Abbvie, Amgen, Arcutis, AstraZeneca, Boehringer Ingelheim, Celgene, Clinuvel, Eli Lilly, Incyte, Janssen Research & Development, LLC, Kadmon Corp, LLC, Leo Pharmaceutucals, Medimmune, Novartis, Ortho Dermatologics, Pfizer, Sciderm, UCB, Inc, and ViDac; and is a consultant for Allergan, Almirall, Arcutis, Inc, Avotres Therapeutics, BirchBioMed Inc, Boehringer-Ingelheim, Bristol-Myers Squibb, Cara Therapeutics, Castle Biosciences, Corrona, Dermavant Sciences, Evelo, Foundation for Research and Education in Dermatology, Inozyme Pharma, LEO Pharma, Meiji Seika Pharma, Menlo, Mitsubishi, Neuroderm, Pfizer, Promius/Dr. Reddy’s Laboratories, Theravance, and Verrica. Dr Leonardi served as a consultant for and/or has been an investigator for and/or is on the speakers bureaus for AbbVie, Actavis, Amgen, Boehringer Ingelheim, Celgene, Coherus, Corrona, Dermira, Eli Lilly & Co, Galderma, Janssen, Merck, Novartis, Pfizer, LEO Pharma, Sandoz, Stiefel, UCB, Vitae, and Wyeth. Dr Mehta is a full-time employee of the United States government and has received support in the form of grants to the National Institutes of Health from AbbVie, Celgene, Janssen, and Novartis. Dr Gottlieb received honoraria as an advisory board member and consultant for AbbVie; Allergan; Avotres Therapeutics; Beiersdorf; Boehringer Ingelheim; Bristol-Myers Squibb Co.; Celgene Corp.; Dermira; Incyte; Eli Lilly & Co.; Janssen; LEO Pharma; Novartis; Reddy Labs; Sun Pharmaceutical Industries, Inc.; UCB; Valeant; and Xbiotech; and has received research/educational grants from Boehringer Ingelheim; Incyte; Janssen; Novartis; UCB; and Xbiotech. Authors Mendelsohn, Parno, and Rozzo are employees of Sun Pharmaceutical Industries, Inc. Dr Menter received grants and/or honoraria as a consultant, investigator, and/or speaker for AbbVie; Abbott Labs; Amgen; Anacor; Boehringer Ingelheim; Celgene; Eli Lilly & Co.; Janssen Biotech, Inc.; LEO Pharma; Merck & Co.; Novartis; Sienna; and UCB; and has been on an advisory board for AbbVie; Amgen; Boehringer Ingelheim; Eli Lilly & Co.; Janssen Biotech, Inc.; LEO Pharma; and Sienna. |
|
| IRB approval status: Reviewed and approved by local Institutional Review Boards at each study site. |
© 2019
American Academy of Dermatology, Inc. Tous droits réservés.
Vol 82 - N° 2
P. 519-522 - février 2020 Retour au numéro
Article précédent
- Microneedling-assisted photodynamic therapy for the treatment of actinic keratosis: Results from a systematic review and meta-analysis
- Theresa Steeb, Anne-Charlotte Niesert, Lars E. French, Carola Berking, Markus V. Heppt
- Current evidence for safety and efficacy of anti–programmed cell-death 1 agents in the treatment of cutaneous squamous cell carcinoma: A systematic review
- Lauren M. Sadowsky, Cory Kosche, Dennis P. West, Jennifer N. Choi
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?